Therefore, our study indicated that development and relapse of MM are likely related to dynamic changes in dysfunctional characteristics of PB CD4 T cells and confirmed recent data showing that immunomodulatory drugs and chemotherapy of MM are preferentially able to delete senescent T cells while retaining checkpoint inhibitory molecule expression [5]. Here, CD4 is linked to Miyoshi myopathy.